Cognitive impairment and functional reorganization in multiple sclerosis: The role of GABA and glutamate - GABA and glutamate in cognitive impairment in MS

VU University medical center Amsterdam0 个研究点开始时间: 2017年8月9日最近更新: 2017年10月23日

试验速览

暂无简介。

•To participate in the MRI part of the study:
•- Clinically definite Relapsing Remitting or Secondary Progressive Multiple sclerosis
•- Sufficient visual acuity and motor performance to perform the MRI task
•- Between 18 and 60 years of age
•To participate in the PET-part of the study:
•- Minimum hemoglobin values of 8 g/dl for men and 7 g/dl for women
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 75
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•For the MRI-part of the study:
•- MR contraindications
•- Neurological and/or psychiatric disorders (other than MS)
•- For MS patients: the use of corticosteroids in the 4 weeks prior to inclusion.
•For the PET-part of the study:
•- benzodiazepine use or other drug use that affects the benzodiazepine receptor system (e.g. antipsychotics that show strong binding to GABAA receptors) 4 weeks or less before the start of the study.
•- In the case of pregnancy or breastfeeding
•- Insufficient haemoglobin value values as discussed in the inclusion criteria.
•- (a history of) significant cardiac disease
•- exposure to previous radiation leading to an annual cumulative dose of more than 10mSv

发起方

VU University medical center Amsterdam